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ABSTRACT
The androgen receptor (AR) is a key molecule
involved in prostate cancer (PC) development and
progression. Post-translational modification of the
AR by co-regulator proteins can modulate its tran-
scriptional activity. To identify which demethylases
might be involved in AR regulation, an siRNA screen
was performed to reveal that the demethylase,
KDM4B, may be an important co-regulator protein.
KDM4B enzymatic activity is required to enhance
AR transcriptional activity; however, independently
of this activity, KDM4B can enhance AR protein sta-
bility via inhibition of AR ubiquitination. Importantly,
knockdown of KDM4B in multiple cell lines results in
almost complete depletion of AR protein levels. For
the first time, we have identified KDM4B to be an
androgen-regulated demethylase enzyme, which
can influence AR transcriptional activity not only
via demethylation activity but also via modulation
of ubiquitination. Together, these findings demon-
strate the close functional relationship between AR
and KDM4B, which work together to amplify the
androgen response. Furthermore, KDM4B expres-
sion in clinical PC specimens positively correlates
with increasing cancer grade (P< 0.001). Con-
sequently, KDM4B is a viable therapeutic target
in PC.
INTRODUCTION
Currently, the control of gene transcription by chromatin
dynamics and interplay between histone modifications is
the subject of detailed investigation. There is much debate
relating to the role of histone modifications in the control
of gene transcription, and it is becoming evident that in
many cases, the role of a particular histone modification is
dependent on the context in which it is found. For
example, tri-methylation on histone H3 at lysine 9
(H3K9Me3) has long been considered a mark of inactive
chromatin; however, this mark can also be found in the
chromatin of active genes (1,2). It seems that rather than
one mark being able to determine the functional output of
an area of chromatin, a combination of marks are
required, and cross-talk between them is important. In
many cases, these marks can act as docking sites for
other proteins to start the chain reaction to transcriptional
activation or repression. This was demonstrated recently,
where to achieve activation of hormone-dependent genes,
the chromatin remodelling NURF complex is recruited
and anchored to chromatin via an H3K4Me3 signal de-
posited by MLL2 and MLL3 and the displacement of the
demethylase, KDM5B. The NURF complex then allows
the recruitment of transcription factors to the promoter
and displacement of the linker histone H1 followed by
displacement of H2A/H2B and the generation of a more
open chromatin structure (3).
Lysine methyltransferases (KMT) and demethylases
(KDM) are proving to be important enzymes that can
control the activity of non-histone proteins. For
example, NF-kB has been found to be mono-methylated
by the KMT, SETD7, to result in increased protein deg-
radation (4). SETD7 can also methylate p53 to increase its
transcriptional activity (5). It is becoming clear that
methylation of non-histone proteins can also functionally
interact with other post-translational modifications, such
as acetylation, suggesting that a whole network of inter-
actions are involved in the regulation of signalling
pathways. It is, therefore, conceivable that both histone
and protein modifications, particularly within transcrip-
tion factors, can also interact to assist in transcriptional
control.
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The androgen receptor (AR) signalling pathway is a key
factor in the development and progression of prostate
cancer (PC). This molecule is subject to many post-
translational modifications, including acetylation (6),
ubiquitination (7) and sumoylation (8), to regulate its
transcriptional activity. Recently, we reported that the
AR can be methylated at lysine 632 (9), which was
followed by the identification of a second methylation
site at lysine 630 (10). Therefore, we propose that methy-
lation and demethylation may be important in the control
of AR-regulated gene transcription, whether it be at the
level of the histone, the level of the AR or interplay
between the two. Some KDM enzymes have already
been reported as co-activators of the AR, including
KDM4D, KDM4A (11) and KDM1A (12).
KDM4B, first identified in 2004 (13), is a member of the
Jmj family of KDMs. Recently, there has been a surge in
KDM4B publications describing its role in transcription.
For example, KDM4B can antagonize H3K9 tri-methy-
lation at pericentric heterochromatin (14), influence
H3K4/H3K9 methylation in hormonally responsive
breast cancer (15) and function as an oestrogen receptor
(ER) co-factor (16). In this study, we identified KDM4B
as an AR co-activator. This is achieved by multiple mech-
anisms, including H3K9Me3 demethylation and H3K9Ac,
as well as increasing AR transcriptional activity and sta-
bility. Furthermore, KDM4B is the first identified AR-
regulated KDM, suggesting this enzyme has a major
role in regulating AR activity and the cellular response
to androgens. Collectively, our data suggest that
KDM4B is a viable therapeutic target for the treatment
of PC.
MATERIALS AND METHODS
Antibodies and constructs
AR (Santa Cruz Biotechnology C-19), KDM4B (Bethyl
Laboratories A301-478A; Thermo Scientific PA5-25354;
Santa Cruz H-200 sc-97192), tri-methyl histone H3
lysine 9 (H3K9Me3) (AbCam), acetylated histone H3
lysine 9 (H3K9Ac) (AbCam), H3 (AbCam), a-tubulin
(Sigma), PSA (Santa Cruz C-19), Ub (Santa Cruz
P4D1), MDM2 (Santa Cruz N-20), p(ARE)3Luc,
pCMV-b-gal (17), pCMV-HA-KDM4B, pCMV-
HA-KDM4B(H189G/E191Q), pGL2-KDM4B(1022/+12),
pGL2-KDM4B(700/+12), pGL2-KDM4B(518/+12) and
pGL2-KDM4B(400/+12) were described previously (18).
Flag-AR and pSG-AR were kind gifts from Ralf
Janknecht (Mayo Clinic, USA) (11). pCDNA3 His
Ubiquitin WT was a kind gift from David Lane
(Singapore) (19).
Cell culture
CWR22rv1 (20) and LNCaP cells were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and maintained in RPMI 1640 media supplemented with
10% (v/v) fetal calf serum and 2mM L-glutamine (Sigma)
at 37C in 5% CO2 atmosphere. LNCaP-CdxR cells were
generated and maintained as described previously (21,22);
LNCaP-AI cells were generated in-house by serially
maintaining LNCaP cells in steroid-depleted media
(SDM) for >9 months. LNCaP-shKDM4B was generated
as described in Supplementary Materials and Methods.
siRNA screen
In this siRNA screen, 78 methylase and demethylase
enzymes were targeted alongside control siRNAs against
Prostate Specific Antigen (PSA), AR and non-silencing
controls. All siRNA sequences were designed by Sigma
using the Rosetta algorithm. Every target had three inde-
pendent sequences generated, which were pooled together
for use in the screen. Individual siRNA sequences are
available in Supplementary Information.
LNCaP cells (4000 cells/well) were reverse transfected
with 25 nM siRNA, consisting of three independent se-
quences pooled together, in SDM using RNAiMax
(Invitrogen) in 96-well plates. Dihydrotestosterone
(DHT) (100 nM) was applied 24 h post-transfection and
incubated for 72 h. PSA secretion and expression were
then assayed as described later in the text. Further
details can be found in Supplementary Materials and
Methods.
PSA enzyme-linked immunosorbent assay
The concentration of PSA secreted into the media was
assessed using a human Kallikrein 3/PSA ELISA
(enzyme-linked immunosorbent assay) (DuoSet ELISA
Development System, R&D Systems) according to the
manufacturer’s protocol. Standard curves were generated,
and PSA concentrations were determined by linear regres-
sion of log(10) normalized absorbance at 450 nm. This
allowed R2 values and the slope of the standard curve to
be calculated, so that interexperimental variation could be
taken into account. Screening with this experimental end
point was performed in duplicate at least three times.
Quantitative polymerase chain reaction
RNA was isolated using TRIzol (Invitrogen) according to
the manufacturer’s protocol. RNA was quantified using
Nanodrop spectrophotometer, and 200 ng of RNA was
reverse transcribed using 1 Moloney Murine Leukemia
Virus (MMLV) buffer (Promega), 60 U MMLV reverse
transcriptase, 0.5 mM oligo d(T)18 (Bioline) and 0.4mM
dNTPs (Bioline) per reaction. Quantitative reverse
transcriptase–polymerase chain reaction (QRT–PCR)
was performed in triplicate for genes of interest using
Platinum SYBR green qPCR SuperMix-UDG
(Invitrogen) in 384-well clear optical reaction plates
using the ABI 7900HT real-time PCR system (Applied
Biosystems) according to the manufacturer’s protocol.
Data were normalized against the house keeping gene
hypoxanthine phosphoribosyltransferase 1 (hprt1). Primers
sequences are described in Supplementary Materials and
Methods.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed in LNCaP cells and LNCaP-shKDM4B cells as
described previously (7). For assays in LNCaP-shKDM4B
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cells, 1 mg ml1 doxycycline was added when cells were
placed into SDM for 72 h to ensure efficient KDM4B
knockdown. For immunoprecipitation, 2 mg of the
appropriate antibody was used, specifically, AR (Santa
Cruz Biotechnology C-19), KDM4B (Bethyl Labora-
tories), tri-methyl histone H3 lysine 9 (H3K9Me3)
(AbCam), acetylated histone H3 lysine 9 (H3K9Ac)
(AbCam) and non-specific isotype control antibodies
(Dako). Purified DNA fragments were then analysed
by QRT-PCR. Primer sequences are detailed in
Supplementary Information. Data represent mean fold
change in percentage input from three independent ex-
periments normalized to 0 h DHT stimulation.
Reporter assays
For all reporter assays, 8  103 Cos7 cells were routinely
plated per well of a 24-well plate (Corning). After 24 h,
cells were transfected using LT-1 reagent (Geneflow) ac-
cording to the manufacturer’s protocol. Assays used to
determine the effect of KDM4B on AR activity
incorporated 200 ng of p(ARE)3-Luc (17) together with
0–75 ng of either pCMV-HA-KDM4B or pCMV-
HA-KDM4B(H189G/E191Q). Assays used to determine AR
regulation of KDM4B transcription incorporated 20 ng of
pGL2-hKDM4B with 0–100 ng of Flag-AR (a gift from R.
Janknecht) or with 50 ng pSGFlag-AR with increasing
concentrations of DHT for 48 h. To determine the area
of the promoter that is responsive to AR stimulation,
deletion constructs of pGL2-hKDM4B were used of the
indicated sizes with 0–100 ng of Flag-AR. Cells were har-
vested in all cases 48 h post-transfection, and luciferase
and b-galactosidase assays were performed as previously
described (23). Each experiment was performed in tripli-
cate and repeated a minimum of three times. Mean fold
change represents induction with DHT compared with
SDM alone normalized to the activity of the
pCMV-driven vector control. Data represent an average
of three repeats± standard error.
Immunoprecipitation
To determine whether AR can interact with KDM4B and
whether the demethylase activity is required for the inter-
action, Cos7 cells grown in RPMI-1640 media containing
10% fetal calf serum were transfected with 1 mg of
Flag-AR and 1 mg of pCMV-HA-KDM4B or 1 mg of
pCMV-HA- KDM4B(H189G/E191Q) after 24 h using LT-1
reagent (Geneflow) according to the manufacturer’s
protocol. Cells were harvested after 48 h and subjected
to immunoprecipitation using anti-AR antibody (Santa
Cruz Biotechnology: C-19) followed by western blotting
with KDM4B antibody (Bethyl Laboratories).
To determine whether AR can interact with endogenous
KDM4B, LNCaP cells were collected and lysed, and AR
was immunoprecipitated using anti-AR antibody (Santa
Cruz Biotechnology: C-19) followed by western blotting
with KDM4B antibody (Bethyl Laboratories). Immuno-
precipitation with anti-HA antibody (Santa Cruz
Biotechnology) was used as a control.
Denaturing immunopreciptitation using Ni-NTA agarose
beads
Cos7 cells were seeded out onto 90-mm dishes and trans-
fected with 1 mg of Flag-AR and 1 mg of pcDNA3 His
Ubiquitin and increasing concentrations (0, 1, 100 and
500 ng) of either pCMV-HA-KDM4B or pCMV-HA-
KDM4B(H189G/E191Q) as described earlier in the text.
After 24 h, 20 mM MG132 (Enzo Life Sciences, UK) was
applied for 16 h. Cells were washed twice with ice cold
phosphate-buffered saline and collected. Input samples
were taken as a 10% volume of cell suspension and resus-
pended in sodium dodecyl sulphate (SDS) loading buffer
[0.125M Tris, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol,
10% (v/v) b-mercaptoethanol and 0.01% (w/v)
bromophenol blue]. Remaining cells were then lysed in 6
ml of lysis buffer (6 M guanidine–HCl, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris–HCl, pH 8, 5mM imidazole and
10mM b-mercaptoethanol) on ice for 30 min. Ni-NTA
agarose beads (Qiagen) were added, and samples were
incubated at 4C overnight with agitation. Agarose
beads were washed for 5 min with agitation with each of
the following buffers. Buffer 1 (6 M guanidinium–HCl, 0.1
M Na2HPO4/NaH2PO4, 0.01M Tris–HCl, pH 8 and
10mM b-mercaptoethanol), buffer 2 (8 M urea, 0.1 M
Na2HPO4/NaH2PO4, 10mM b-mercaptoethanol and
0.01 M Tris, pH 8), buffer 3 [8 M urea, 0.1 M
Na2HPO4/NaH2PO4, 10mM b-mercaptoethanol, 0.01 M
Tris, pH 6.3 and 0.2% (v/v) Triton X-100] and buffer 4 [8
M urea, 0.1 M Na2HPO4/NaH2PO4, 10mM b-merca-
ptoethanol, 0.01M Tris, pH 6.3 and 0.1% (v/v) Triton
X-100]. Samples were then eluted from the beads in 50 ml
of elution buffer [200 mM imidizole, 0.1 M Na2HPO4/
NaH2PO4, 0.15M Tris–HCl, pH 6.7, 10mM b-mercap-
toethanol, 30% (v/v) glycerol and 5% (w/v) SDS] for 20
min with agitation at room temperature. Elutes were
mixed 1:1 with SDS loading buffer and analysed by
western blotting using AR antibody (BD).
Denaturing antibody-mediated immunoprecipitation
Cos7 cells were seeded, transfected and treated with
MG132 as described earlier in the text. Cells were col-
lected in IP lysis buffer containing 20% SDS and boiled
for 10 min. Ten per cent inputs were then taken, and SDS
sample buffer was added at a 1:1 ratio. The remaining cell
lysate was then diluted in non-SDS containing lysis buffer
to allow antibody use. Two micrograms of either anti-AR
or anti-Ubiquitin antibody was then added and incubated
at 4C overnight with gentle rotation. Protein G
Sepharose was added for 4 h. Bead–antibody complexes
were then washed 4–6 times in 0.5 M KCl then once in
0.1 M KCl. Beads were re-suspended in SDS loading
buffer and analysed by western blotting.
Proliferation assays
PC cell lines were seeded out in full media onto 96-well
plates and reverse transfected with 25 nM siRNA using
RNAiMax according to the manufacturer’s protocol.
Oligonucleotide concentrations were normalized using
N/S siRNA. After three doubling times, proliferation
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was assessed using WST-1 reagent (Roche) according to
the manufacturer’s protocol. Experiments were performed
in repeats of six and performed three times. All data were
normalized to N/S for each cell line.
Immunohistochemistry
IHC was performed on tissue microarray (TMA) contain-
ing 0.6-mm cores of benign prostatic hyperplasia (BPH)
and PC tissue from each sample and control tissue, such as
breast, kidney, adrenal, placenta, ovary, lung and liver.
Slides were baked for 2 h at 60C to remove moisture,
de-paraffinized with xylene and hydrated with varying
concentrations of ethanol. Endogenous peroxidase
activity was quenched with 0.5% H2O2 in methanol.
Epitope retrieval by pressure cooking in 0.01M citrate
buffer, pH 6.0, was performed before primary antibody
application. Slides were incubated with goat serum for
30min; then primary KDM4B antibody (Bethyl
laboratories) was applied (1:250) in phosphate-buffered
saline and incubated overnight at 4C. Biotinylated goat
anti-rabbit secondary antibody was used to detect the
bound primary. ABC kit (Vector Laboratories) and
3,3-Diaminobenzidine (DAB) were used for detection of
immuno-reactivity. The immuno-reactivity scoring was
done by two experienced uro-pathologists. The signal in-
tensity of the epithelial cancer cells was scored according
to the intensity and was categorized into weak, moderate
and strong cytoplasmic signal groups.
Statistical analyses
Mann–Whitney U-test and Kruskal–Wallis test were used
to correlate expression of KDM4B with benign prostate
and grades of PC. Patient survival analysis used Kaplan–
Meier plots with log-rank statistical testing. Tests were
undertaken using SPSS, version 11.0, computer software
(SPSS Inc.). A P-value of <0.05 was taken to indicate
statistical significance.
RESULTS
KDM4B regulates AR-mediated transcription
To identify which KDM enzymes are involved in AR
signalling, an siRNA screen was performed in the PC
cell line, LNCaP, using a pool of three independent
siRNA sequences per enzyme. After knockdown for 48 h
in SDM, DHT (100 nM) was applied to stimulate the AR
signalling pathway. Media were collected 72 h later, and
PSA ELISA was used as a high-throughput method to
determine whether AR signalling was affected. KDM4B
was identified as an AR co-regulator, as knockdown
decreased PSA secretion by 38% (Figure 1A). QRT-
PCR analysis confirmed a 33% reduction in PSA
mRNA levels (Figure 1B), which was authenticated
further using three independent siRNA sequences
(Figure 1C) (P< 0.005) to knockdown KDM4B (Figure
1D). In comparison with the knockdown of AR, the effect
of KDM4B depletion on PSA levels may be considered
modest. However, there are many reasons why this may
occur. For example, there may be other factors in the
pathway that can affect the expression of PSA independ-
ently of KDM4B, whereas AR is the key regulator; there-
fore, AR knockdown will have the greatest impact on PSA
levels. Second, knockdown of KDM4B is not the same as
knockout. Therefore, any residual KDM4B in the cells
may contribute to PSA expression. However, we can
rule out the effects of other KDM4 family members, as
these remain unaltered in response to KDM4B
knockdown (Supplementary Figure S1G).
To confirm that KDM4B is involved in androgen re-
sponsive gene expression as a whole and not just PSA
expression, DHT stimulation time courses were performed
post-KDM4B knockdown in a number of AR positive PC
cell lines, including LNCaP (Figure 2), LNCaP-CdxR (22)
and LNCaP-AI cells (Supplementary Figure S1). A panel
of androgen-regulated genes were investigated by QRT-
PCR including PSA, Kallikrein-related peptidase 2
(KLK2), transmembrane protease, serine 2 (TMPRSS2),
NKX3.1 and N-myc downstream regulated 1 (NDRG1).
As shown in Figure 2, knockdown of KDM4B inhibits
androgen responsive gene expression of all the genes
tested, robustly demonstrating a role for KDM4B in the
AR signalling pathway.
KDM4B regulates AR-mediated transcription by
modulating histone post-transcriptional modifications in
response to androgens
KDM4B has been shown to demethylate histone H3 at
lysine 9, albeit with a weaker activity than other KDM4
family members (14). It can remove tri-methyl marks to
leave either a mono- or a di-methyl species. The response
to this removal can include transcriptional activation, and
indeed removal of methyl marks on lysine 9 has already
been implicated in activation of androgen-regulated genes
(24,25). To determine whether this could be the mechan-
ism through which KDM4B functions here, a series of
ChIP assays were performed to determine the status
of particular histone marks in response to DHT, and
whether KDM4B is found at the promoters of androgen
responsive genes. In response to DHT stimulation, a
6.5-fold enrichment of AR was observed at the AREIII
sequence within the PSA promoter (Figure 3A). KDM4B
was found to be present and enriched by 2.7-fold after 30
min of DHT stimulation. However, after 120 min,
KDM4B was absent (Figure 3B), whereas AR continued
to be enriched, suggesting KDM4B functions early in the
transcriptional response to DHT. Alternatively, KDM4B
may cycle on and off the chromatin similar to other tran-
scription factors including the AR (26). Furthermore, in
response to DHT, a significant reduction in the repressive
H3K9Me3 (Figure 3C) was observed (P< 0.005) further
supporting a role for KDM4B in histone modification at
androgen responsive genes. As there have been many links
made between methylation and acetylation of histones, the
levels of H3K9Ac were also investigated. Increases in
H3K9Ac are associated with transcriptional activation,
and indeed increases were observed at the PSA
promoter in response to DHT (Figure 3D). It seems that
once the tri-methyl mark has been removed, the acetyl-
ation mark increases at 120 min post-DHT stimulation.
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This may suggest a requirement for interplay between
demethylation and acetylation to achieve efficient andro-
gen-stimulated gene expression.
Removal of H3K9Me3 in response to DHT may be a
consequence of other enzymes functioning at the same
time point, which has been demonstrated previously for
KDM4C and KDM1A (25). To further demonstrate that
KDM4B plays a role in events observed on the chromatin
in response to DHT, a stably inducible shRNA LNCaP
cell line was generated: LNCaP-shKDM4B. When doxy-
cycline (1mg ml1) is applied to this cell line, the shRNA
against KDM4B is expressed, which results in KDM4B
knockdown (Supplementary Figure S2A) and inhibition
of PSA expression in response to DHT stimulation
(Supplementary Figure S2B). ChIP assays were performed
in LNCaP–shKDM4B cells stimulated with doxycycline
on starvation in SDM for 72 h. DHT (100 nM) was
applied to the cells for 0 and 120 min followed by formal-
dehyde fixation and chromatin collection. In the absence
of doxycycline, a 2-fold enrichment of AR was found
at the AREIII sequence within the PSA promoter
(Figure 3E) and a 6-fold enrichment at KLK2 and
TMPRSS2 promoters (Supplementary Figure S2C and
D). However, on KDM4B knockdown (Figure 3F), this
was reduced to basal levels supporting the theory that
KDM4B may be required for AR to efficiently associate
with chromatin. It also seems that KDM4B functions in
the removal of H3K9Me3 in response to androgens, as
when KDM4B is knocked down, an increase in
H3K9Me3 was observed (Figure 3G). In addition, when
KDM4B was knocked down, H3K9Ac was considerably
reduced (Figure 3H), indicating that the removal of
H3K9Me3 and the appearance of H3K9Ac are linked.
As the effect on H3K9Me3 was not seen at the global
level (Figure 3I), this effect seems to be specific to this
region of the chromatin.
KDM4B interacts with the AR and enhances its
transcriptional activity
Although KDM4B may play a role in this signalling
pathway at the level of the histone, it may also be able
to coactivate the AR. Previously, other members of the
KDM4 family have been shown to interact with, and
coactivate the AR (25); however, this has not been
shown for KDM4B to date. To address this, Cos7 cells
were transiently transfected with wild-type AR (Flag-AR)
and wild-type KDM4B, followed by AR immunopre-
cipitation. Western analysis demonstrated that KDM4B
can interact with AR under these conditions
(Figure 4A). Furthermore, an endogenous interaction
between KDM4B and AR was confirmed in LNCaP
Figure 1. KDM4B is a putative AR activity regulator. (A) LNCaP cells grown in SDM were transiently transfected with a pool of three independent
siRNA sequences targeting KDM4B in SDM for 24 h before DHT (100 nM) stimulation for a further 72 h. Non-silencing (N/S), AR and PSA
siRNAs were also included as controls. PSA ELISA (R&D systems DuoSet) and (B) QRT-PCR was performed to detect PSA mRNA levels. (C)
LNCaP cells grown in SDM were transiently transfected with individual siRNA oligos targeting KDM4B in SDM 24h before DHT (100 nM)
stimulation followed by RNA extraction and QRT-PCR for PSA mRNA expression (*P< 0.05). KDM4B knockdown was confirmed by (Di) QRT-
PCR and (Dii) western blotting. All QRT-PCR data were normalized to HPRT1, and a-tubulin was used as a loading control on western blots. All
experiments were performed twice or more times, and data represent the mean fold change±SE.
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cells (Figure 4B). To determine whether the catalytic
activity is required for this interaction between AR and
KDM4B, a KDM4B construct that has been mutated
within the JmjC domain (H189G/E191Q), to render it
catalytically inactive (18), was used. Western blotting
revealed that the catalytic activity is not required for
KDM4B to interact with the AR (Figure 4A).
To investigate whether KDM4B can increase the tran-
scriptional activity of the AR, reporter assays were per-
formed using p(ARE)3-luc (17) in conjunction with AR
and increasing amounts of KDM4B. When KDM4B
was overexpressed, AR activation induced by DHT
increased from 2.7- to 5.3-fold, suggesting that KDM4B
can coactivate the AR (Figure 4C). To test whether the
demethylase activity is required for this increased AR
transactivation, the demethylase null form of the enzyme
was used instead of the wild-type. Here, there was no
change in the transactivation of AR, suggesting that the
demethylase activity is important for the effects on AR
activity (Figure 4C).
KDM4B can increase AR protein stability by inhibiting
AR ubiquitination
On western blotting to demonstrate expression of
Flag-AR with increasing levels of KDM4B in Cos7 cells,
we observed that although eqimolar quantities of AR were
transfected, AR levels increased (Figure 5A). Similarly,
AR became stabilized by KDM4B(H189G/E191Q), but AR
transactivation was absent (Figure 4C), suggesting that
the KDM activity is required to maximally enhance AR
activity. Similar results were obtained when the AR was
expressed from a Simian vacuolating virus 40 (SV40)
promoter (Supplementary Figure S2E), ruling out
increased levels being because of activation of the
pCMV promoter. As overexpression of KDM4B seems
to increase the levels of AR protein when AR is expressed
from a pCMV (or SV40) promoter suggesting an effect on
protein stability, this raised the question of whether
KDM4B knockdown can result in a de-stabilized AR
and, therefore, reduced AR levels. To investigate this
further, transient knockdown of KDM4B was performed
in LNCaP cells for 48 h, and the levels of AR protein were
assessed by western blotting. Indeed, this revealed that
knockdown of KDM4B results in reduced AR levels
(Figure 5B). Moreover, this was also tested in cell lines
that are androgen independent (LNCaP-AI) and resistant
to anti-androgen therapy (LNCaP-cdxR) to reveal similar
findings (Figure 5C).
AR turnover is controlled via the ubiquitin–proteasome
pathway (27), and in histone biology, there is increasing
evidence that methylation and ubiquitination are closely
linked (28). Therefore, the level of AR ubiquitination
(AR-Ub) was assessed in the presence and absence of
KDM4B by denaturing immunoprecipitation in Cos7
cells transfected with AR- and His-tagged ubiquitin. On
stimulation with DHT, AR-Ub was reduced (Figure 5D,
lane 4); however, when either KDM4B or
KDM4B(H189G/E191Q) was added, AR-Ub was lost
(Figure 5D, lanes 5–8). This was further confirmed by
performing an antibody-based denaturing IP protocol
detailed in ‘Material and Methods’ section demonstrating
AR-Ub in the presence ofMG132, which is abolished when
KDM4B is added (Figure 5E). The reciprocal IP using an
anti-Ubiquitin antibody also supported these data
Figure 2. KDM4B is important for AR-mediated transcription. LNCaP cells with KDM4B knockdown were stimulated with DHT (100 nM) for
72 h. (A) PSA, (B) KLK2 (C) TMPRSS2, (D) NKX3.1, (E) NDRG1 and (F) KDM4B levels were assessed >72 h by QRT-PCR and normalized to
HPRT1. A non-silencing (N/S) oligo was used as a control. Data are expressed as mean fold change compared with N/S without DHT
stimulation±SE.
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(Supplementary Figure S2F). This effect also seemed to be
KDM4B dose dependent (Figure 5F), and interestingly,
although KDM4B(H189G/E191Q) can also inhibit AR-Ub, it
seems to be deficient in this process (Figure 5G), as both the
mutant andwild-type forms are expressed at the same levels
(Supplementary Figure S2G), with only higher KDM4B
concentrations being able to influence AR-Ub.
KDM4B was confirmed as ubiquitinated (Supplementary
Figure S2H); however, overexpression of His-tagged
Ubiquitin ensures that KDM4B should not be able to
‘mop up’ all the Ubiquitin within the cell. Therefore, we
conclude that this decrease in AR-Ub is a genuine affect.
Because of the role of the E3 ubiquitin ligase, MDM2,
in AR-Ub and that another KDM4 family member,
KDM4C, has been described to enhance MDM2 levels
(29), we questioned whether MDM2 levels were affected
by KDM4B. However, increased AR stability seems to be
via the prevention of AR-Ub, as we found no evidence
of altered MDM2 levels with KDM4B knockdown
(Figure 5H). We speculate that this is due to the structural
interaction between KDM4B and AR masking ubiquitin
acceptor sites. The novel role for KDM4B in
ubiquitination inhibition and AR degradation warrants
further investigation, but it is encouraging to note that
interplay between various modifications is just as import-
ant here as on histone proteins.
KDM4B is an androgen-regulated gene
As KDM4B and AR seem to be functionally linked, it
would be logical for KDM4B levels to increase in
response to DHT, allowing AR and KDM4B to cooperate
and promote AR transcriptional events. To test this
theory, KDM4B mRNA and protein levels were assessed
in response to DHT in LNCaP cells revealing that, indeed
KDM4B mRNA (Figure 6A) and protein (Figure 6B) are
androgen regulated. This was further confirmed by gene
reporter assays, where Cos7 cells were co-transfected with
AR and pGL2-human KDM4B luciferase construct (18),
containing the KDM4B promoter (1022/+12) sequence
upstream of a luciferase gene, where increasing doses of
DHT (Figure 6C) and increasing AR levels (Figure 6D)
significantly enhanced KDM4B reporter activity
(P< 0.05). As this is the first example of a demethylase
enzyme being androgen regulated, the KDM4B promoter
was analysed for potential androgen response elements
within its promoter sequence using Genomatix software
Figure 3. KDM4B is required for AR recruitment, H3K9Me3 removal and H3K9Ac addition at androgen-regulated genes. ChIP for (A) AR,
(B) KDM4B, (C) H3K9Me3 and (D) H3K9Ac at the PSA promoter in LNCaP cells treated with DHT (100 nM) for 0, 30 and 120min. Non-specific
IgG was used as a negative control. (E) ChIP analysis for AR at the PSA promoter in LNCaP-shKDM4B cells treated with and without doxycycline
for 72 h and 100 nM DHT for 0 and 120min. Data are shown as mean fold change of IgG normalized data compared with time 0 from two or more
independent experiments±SE (***P< 0.0005). (F) KDM4B and AR levels were assessed by western blotting in both LNCaP-shKDM4B and the
control cell line LNCaP-shN/S in the presence and absence of doxycycline. (G) ChIP analysis for H3K9Me3 and (H) H3K9Ac at the PSA promoter
in LNCaP-shKDM4B cells treated with and without doxycycline for 72 h and 100 nM DHT for 0 and 120min. (I) Global histone modifications.
Histone H3 and a-tubulin were used as loading controls.
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(www.genomatix.de). This revealed three potential AR-
binding sites 3000 bases from the transcription start
site (TSS) (Supplementary Figure S3), one of which
resides in the sequence incorporated within the luciferase
construct. To identify whether AR can directly bind the
DNA sequence incorporated within the luciferase con-
struct, ChIP assays were performed in LNCaP cells in
response to DHT over time, and primers were designed
to span an area within the sequence. In response to
androgen stimulation, the AR was significantly enriched
by 6-fold at the KDM4B promoter (P< 0.005), confirming
that KDM4B is indeed an AR-regulated gene (Figure 6E).
To further isolate the region of androgen dependence,
deletion constructs were used (18), which were all respon-
sive to AR stimulation, suggesting that the site of
androgen regulation lies within the first 400 base pairs
upstream of the TSS (Figure 6F) contradictory to the
Genomatix predictions. However, after further inspection,
a putative ARE was found within this region (Figure 6G).
To test whether this site is functional, one of the half sites
of the ARE was mutated within the luciferase construct
that resulted in an 50% decrease in fold induction in
response to DHT (Figure 6H), suggesting that the
identified ARE is indeed functional (P-value=0.006).
KDM4B is important for cell proliferation via its
regulation of the AR
KDM4B regulates AR levels; therefore, KDM4B knock-
down may result in a similar phenotype to AR knockdown.
To test this hypothesis, a series of AR-positive cell lines
were transfected with siRNA against N/S, AR, KDM4B
or both KDM4B and AR together, and proliferation was
assessed. As controls, two AR-negative cell lines, DU145
and PC3, were used. On AR or KDM4B knockdown, pro-
liferation was reduced in all AR-positive cell lines but not in
AR-negative cell lines (Figure 7A), suggesting that the
effects on proliferation are mediated by AR function.
Although AR knockdown has been reported to result in a
62% reduction in LNCaP proliferation (30), this was
apparent after 11 days by colony forming as opposed to
3.5 days that was used here. However, LNCaP-shKDM4B
cells demonstrated a reduced colony-forming ability
(75%) on KDM4B knockdown (data not shown). When
both AR and KDM4B were knocked down, proliferation
was inhibited further, again a phenomenon not observed in
AR-negative cell lines (Figure 7A). Interestingly,
LNCaP-CdxR, a model of PC, which has relapsed treat-
ment with Bicalutimide (CasodexTM), showed 40% reduc-
tion in proliferation, demonstrating that decreased AR
levels in response to KDM4B knockdown do result in a
beneficial functional outcome.
KDM4B dysregulated expression can be associated with
increasing grade of prostate cancer
As KDM4B seems to be a key molecule in the regulation
of AR levels within PC cells, the expression of this
demethylase was assessed in human PC clinical material
(Figure 7B, Supplementary Figures S4–S6). In total, 78
BPH controls and 187 PC cases were included in this
study, all of which have long-term follow-up clinical in-
formation available. Newly diagnosed, treatment naı¨ve
and paired relapse samples are included in this sample
set. Increased immunoreactivity for KDM4B was seen in
PC compared with BPH (P< 0.001) (Figure 7C), which
correlates with the findings of Cloos et al. (31) where tran-
scripts were found to be upregulated in PC compared with
normal tissue. Moreover, a trend for increasing KDM4B
cytoplasmic staining is associated with increasing Gleason
grade (P< 0.001) (Figure 7D), suggesting a correlation
with increasingly aggressive PC. On correlation of
KDM4B staining intensity with clinical PC outcomes,
time to hormone relapse (Figure 7E) and overall survival
(Figure 7F), we observed divergent curves on Kaplan–
Meier graphs; however, this pattern is not statistically sig-
nificant. Although traditionally this KDM is described for
its action against nuclear histone proteins, it is evident that
in PC, there may be other cytoplasmic roles for this
Figure 4. KDM4B interacts with AR and coactivates the AR via its
demethylase activity. (A) AR was immunoprecipitated from Cos7 cells
transfected with Flag-AR and pCMV-HA-KDM4B or pCMV-HA-
KDM4B(H189G/E191Q) and analysed by western blotting with anti-AR
and anti-KDM4B. (B) Endogenous AR was immunoprecipitated from
LNCaP cells and analysed by western blotting with anti-AR and
anti-KDM4B. Negative controls are included as extracts (cell lysates
without antibody addition) and Ab only (an antibody only control in
the absence of cell lysate), (C) Cos7 cells transfected with Flag-AR and
increasing concentrations of either pCMV-HA-KDM4B (wt-KDM4B)
or pCMV-HA-KDM4B(H189G/E191Q) (mt-KDM4B) together with
ARE3-luciferase and b-galactosidase reporter, were stimulated with
DHT (100 nM) for 48 h followed by luciferase and b-galactosidase
assays. All DNA concentrations were adjusted with empty vector
plasmids. All experiments were performed twice or more times, and
data are expressed as mean fold change±SE.
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protein, as two other studies have also reported cytoplas-
mic localization (32,33). Indeed, strong cytoplasmic
staining was associated, although not statistically signifi-
cant, with decreased survival and time to relapse. This is
an intriguing finding, as on cellular fractionation of
LNCaP cells, KDM4B is found to be completely nuclear
(data not shown). However, two independent antibodies
have been tested and found to display the same staining
patterns: a mixture of cytoplasmic and nuclear staining in
prostate tissues (Supplementary Figure S5). The nuclear
staining that was observed (Figure 7, Supplementary
Figures S4 and S6) showed no correlation in this data
set, with Gleason grade.
DISCUSSION
The known regulatory mechanisms of the AR have sub-
stantially increased in complexity during the past decade.
This has revealed the roles of many other proteins in the
process, particularly those capable of post-translationally
Figure 5. KDM4B inhibits AR ubiquitination. (A) Total cell lysate from Cos7 cells transfected with 1mg of Flag-AR and increasing concentrations
(0, 1, 100 and 500 ng) of either pCMV-HA-KDM4B or pCMV-HA- KDM4B(H189G/E191Q) were analysed by western blotting (WB) with anti-AR and
anti-KDM4B. a-tubulin was used as a loading control. KDM4B was knocked down in (B) LNCaP, (C) LNCaP-AI and LNCaP-cdxR cells and
analysed by WB using anti-AR, anti-KDM4B and anti-PSA. a-tubulin was used as a loading control. (D) Denaturing IP was performed on cell
lysates from Cos7 cells transfected with Flag-AR, His-tagged ubiquitin (Ub), pCMV-HA-KDM4B or pCMV-HA-KDM4B(H189G/E191Q) then treated
with DHT (100 nM) or vehicle control for 16 h in the presence of MG132 (20mM). WB was carried out using anti-AR. (E) Ub was immunopre-
cipitated post-protein denaturation from Cos7 cells transfected with Flag-AR, His-tagged Ub and pCMV-HA-KDM4B and was treated with MG132
or vehicle control for 16 h using anti-Ub antibody and analysed by WB with anti-AR. Cos7 cells were transfected with Flag-AR, His-tagged Ub and
increasing concentrations (0, 1, 100 and 500 ng) of pCMV-HA-KDM4B (F) or pCMV-HA-KDM4B(H189G/E191Q). (G) MG132 was applied for 16 h
before denaturing IP and WB with anti-AR. (H) MDM2 levels in LNCaP cells with KDM4B knockdown. All DNA concentrations were adjusted
with empty vector plasmids.
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modifying the receptor to impact on its activity. Further-
more, many of these additional factors have been shown
to function as oncogenes in PC development and progres-
sion. In addition, as many castrate-resistant cancers still
express the AR, targeting its regulatory proteins to indir-
ectly manipulate the AR in disease is a viable therapeutic
option. In this study, the KDM enzyme KDM4B was
identified as a novel AR regulator. KDM4B can not
only facilitate the demethylation of histone proteins at
androgen-regulated chromatin, but it can also impact on
other post-translational modifications of histone proteins
to facilitate transcriptional activation. Furthermore, the
demethylase activity of this protein assists the transcrip-
tional activity of the AR. Most interestingly, KDM4B can
also regulate the levels of the AR protein independently of
its demethylase activity. On knockdown of KDM4B in
multiple cell lines, the levels of AR are significantly
reduced, whereas overexpression of KDM4B can stabilize
the AR protein. The mechanism through which this occurs
seems to be via the prevention of AR-Ub. We speculate
that this is due to the structural interaction between
KDM4B and AR, masking the sites of ubiquitination or
resulting in E3 ubiquitin ligases being unable to bind the
AR. Consequently, knockdown of KDM4B results in a
Figure 6. KDM4B is an androgen responsive gene. KDM4B levels were assessed by (A) QRT-PCR and (B) western blotting in LNCaP cells
stimulated with DHT (100 nM) >72 h. HPRT1 and a-tubulin were used as respective loading controls. Cos7 cells were transfected with
b-galactosidase (b-gal) and KDM4B-luciferase reporter (18) with either (C) AR with increasing DHT concentrations or (D) increasing AR concen-
trations for 48 h. Luciferase activity was normalized to b-gal controls. Data represent mean fold change of three independent experiments±SE. (E)
ChIP of AR at the KDM4B promoter in LNCaP cells treated with 100 nM DHT for 0, 30 and 120min. (F) Cos7 cells were transiently transfected
with KDM4B-luciferase deletion reporter constructs [pGL2-KDM4B(1022/+12), pGL2-KDM4B(700/+12), pGL2-KDM4B(518/+12) and
pGL2-KDM4B(400/+12)] (18) together with b-gal reporter and 0, 50 or 100 ng of AR for 24 h before DHT (100 nM) stimulation for 48 h.
Luciferase activity was determined as described earlier in the text. (G) Putative androgen response element within the KDM4B promoter is underlined
in bold. The TSS is denoted in italic. (H) Cos 7 cells were transfected with either pGL2-KDM4B(1022/+12) or pGL2-KDM4Bmt
1 together with b-gal
reporter and AR for 24 h before DHT (100 nM) stimulation for 48 h. Luciferase activity was determined as described earlier in the text. Data are
expressed as mean fold change between wild-type and mutant reporter activity in response to DHT stimulation from four independent experiments
(*P< 0.05; **P< 0.005).
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reduction in proliferation similar to that of AR
knockdown, whereas increased KDM4B expression was
found in PC specimens that correlated with increasing
grade of cancer. KDM4B itself was also found to be
androgen regulated, suggesting the presence of an ampli-
fication strategy between the AR and KDM4B to achieve
a maximal response to androgen stimuli. This is similar to
that proposed for ER signalling by Shi et al. (15), which
was published during the preparation of this manuscript,
although they do not mention the effects of KDM4B on
ER ubiquitination. As KDM4B can increase the levels of
AR and its demethylase activity is required to increase AR
Figure 7. KDM4B associates with increased Gleason grade, decreased survival and reduced time to relapse. (A) Cell lines were reverse transfected
with non-silencing (N/S), AR, KDM4B or KDM4B and AR together. After three doubling times, proliferation was determined by WST-1 assay
(Roche). Data represent mean of three independent experiments with each cell line normalized to N/S controls±SE. (B) Representative KDM4B
staining of prostate tissue using anti-KDM4B antibody in immunohistochemistry. C denotes evidence of cytoplasmic staining and N denotes evidence
of nuclear staining. (C) Analysis of TMA staining for KDM4B using a Mann–Whitney test shows increased KDM4B in CaP compared with BPH
(P< 0.001), and (D) KDM4B increases with CaP grade (*P< 0.05; **P< 0.005). Kaplan–Meier analysis demonstrates statistically insignificant trend
between KDM4B staining, (E) time to relapse and (F) survival.
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activity, the development of a specific KDM4B inhibitor
would be highly beneficial.
In response to androgen stimulation, KDM4B was
found to be recruited to the promoters of androgen re-
sponsive genes, where it was able to demethylate
H3K9Me3. We have also found that the activity of
KDM4B is required for H3K9Ac to occur, which is not
surprising because K9 methylation and acetylation are
mutually exclusive (34). Cross-talk with other histone
modifications is also likely to occur. For example,
MLL2 has been described as a KDM4B interacting
protein that can help to regulate the levels of H3K4
methylation at ER-regulated genes (15). Interestingly,
MLL2 was also identified in our initial siRNA screen as
a potential co-activator of the AR. MLL2 is enriched
3-fold at AR-regulated promoter regions in response to
DHT stimulation and its knockdown results in the inhib-
ition of AR-regulated gene expression, whereas the levels
of AR themselves remain constant (data not shown). It
would be interesting to determine whether KDM4B can
also regulate the levels of H3K4Me3 and the activity of
MLL2 in PC cell lines too, as H3K4Me3 marks have been
described as binding surfaces for proteins containing PHD
domains, specifically the ING family of acetyltransferases.
As this study provides evidence for the interplay between
methylation and acetylation, this leads us to speculate that
MLL2 is required to produce H3K4Me3 for the appropri-
ate acetyltransferase to bind and subsequently acetylate
H3K9 after removal of H3K9Me3 to continue chromatin
signalling towards a transcriptional response.
KDM4B was first suggested to be a p53 target gene via
gene expression analysis in TP53-depleted cells treated
with 5-fluorouracil (35). More recently, it has also been
robustly described in two studies as an Hypoxia Inducible
Factor 1-alpha (HIF-1 a) regulated gene (18,36), and most
recently as an ER-regulated gene (33). To further add to
the complexity of the regulation of this gene, evidence
presented here demonstrates that KDM4B can also be
regulated by AR. However, unlike the Oestrogen
response Element (ERE) identified within intron 1 of
KDM4B, a putative ARE resides within 400 bp of the
TSS. After more detailed analysis of this sequence, a
putative ARE was found 221 bp from the TSS. ChIP
confirmed AR binding to this region of the chromatin,
and a mutation in one of the half-site results in a reduction
in response to AR by 50%, suggesting that this site is
functional. Furthermore, other potential AR-binding
sites were also identified upstream of the TSS, which
have not been investigated, providing the potential for
other sites to be functionally identified. ChIP-Seq studies
have also identified KDM4B as a putative AR-regulated
gene. Massie et al. (37) found KDM4B to be upregulated
in response to androgens after 5 h, but found no change
before this. On analysis of their data by Rivera-Gonzalez
et al. (38), six androgen response elements were identified
close to the KDM4B gene. Guseva et al. (39) also
identified KDM4B as an AR-regulated gene by
ChIP-Seq in LNCaP cells. Furthermore, Wyce et al. (40)
identified an AR active region with a peak value of 2.612
in muscle cells stimulated with 30 nM DHT for 8 h. This
was a similar peak height to TMPRSS2, which had one
active region with a peak value of 2.733. Yet, the majority
of studies looking for AR-regulated genes did not identify
KDM4B. This may be due to experimental variations. For
example, Chen et al. (41) applied DHT for 2 h , whereas
Urbanucci et al. (42) applied DHT for 2 and 24 h.
Given that the AR can exhibit greater stability when
KDM4B is overexpressed, and AR can upregulate
KDM4B; a positive feedback loop is evident between
these two molecules to amplify the androgenic signal.
This is similar to that proposed for ER signalling, which
was published during the preparation of this manuscript
(15). However, KDM4B is not only an androgen-
regulated gene but, unlike the ER, it can also hinder AR
ubiquitination and subsequent degradation to further
amplify the androgenic signal. Indeed, it seems that
KDM4B is required for the AR protein to function
within the cell because of the extent of AR depletion
when KDM4B is knocked down. This novel role for
KDM4B involvement in the inhibition of ubiquitination
and degradation of the AR warrants further study.
Another KDM4 family member, KDM4C, has been
described to enhance the levels of the E3 ubiquitin
ligase, MDM2 (29), a phenomenon which does not hold
true with KDM4B (Figure 5H). The mechanism by which
the effect occurs requires further investigation, but it is
encouraging to note that interplay between various modi-
fications is just as important here as on histone proteins.
Furthermore, it may be proposed that targeting the inter-
action between AR and KDM4B in a similar way to the
interaction between MDM2 and p53 would be of benefit
to PC patients. However, investigation into the viability of
this strategy is required. Alternatively, the demethylase
activity is required to enhance the transcriptional
activity of the receptor rendering its enzymatic activity a
drug target.
The links between KDM4B and hypoxic response are
also important. It is well documented that androgen with-
drawal in patients leads to hypoxia (43), and that hypoxia
increases AR activity and androgen-regulated gene expres-
sion (44,45). Our studies suggest that the mediator of these
effects could be KDM4B. KDM4B has been reported to
be a transcriptional target of HIF (18); hence, if hypoxia
results in increased expression of KDM4B that can stabil-
ize the AR and increase its transcriptional activity and,
therefore, enhance androgen-regulated gene expression,
this would account for the findings in these studies.
Furthermore, the finding that cytoplasmic levels of
KDM4B are associated with increasing grade, decreased
survival and reduced time to relapse in PC patients may be
due to increased stability of the AR in this compartment.
This could imply that the cells would be more responsive
to lower levels of circulating androgens. This further
supports the role of KDM4B as an oncogene in PC and
provides a mechanism for KDM4B to be expressed under
an androgen-ablated environment.
In summary, our data propose that to obtain efficient
androgen-regulated gene transcription, there has to be
coordination of events at the histone level, which must
interplay with transcription factor post-translational
modifications. First, the receptor is activated by its
ligand and shuttled to the nucleus of the cell where,
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together with its coactivator proteins, the local histone
environment is altered by a flux of methylation,
demethylation and acetylation events. KDM4B may be
one of the initiator molecules in this pathway, as
demethylation is certainly required to occur on lysine 9
of histone H3 for acetylation to occur. We have also
identified methylases, not discussed here (manuscript in
preparation), which may play a role in this chain of
events. Because of the close relationship between AR
and KDM4B identified here, we believe that KDM4B
will prove to be a key therapeutic target in coming years
not only for androgen-dependent PC but also for, more
importantly, PCs that have relapsed conventional
treatments.
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